Cure4Cancer

My biggest highlight from the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting was the multi-stakeholder reception for the Bloomberg New Economy International Cancer Coalition. Here global industry, academia and government leaders shared their insights and expressed support for international collaboration on cancer trials, with keynote addresses by the FDA's "Cancer Czar" Dr. Rick Pazdur, ASCO Chief Medical Officer Dr. Julie Gralow, and Director of the National Cancer Institute (NCI) Dr. Kimryn Rathmell. We discussed global infrastructure building and policy harmonization in China, Australia, Nigeria, Brazil and beyond. Through leapfrog technologies and global collaboration, all these initiatives will help us accelerate cancer breakthroughs and expand access to precision oncology in the local communities in the U.S. Global is local, that is the future. Let’s spread the word. #cancer #oncology #clinicaltrials #international #collaboration #technology #healthequity #Cure4Cancer

The Bloomberg New Economy International Cancer Coalition recently concluded its annual meeting alongside the American Society of Clinical Oncology (ASCO) event, emphasizing the critical need for international cooperation and regulatory alignment to accelerate life-saving cancer treatments. Key Highlights: 1. The FDA's Role in International Cooperation - Richard Pazdur, Director of the FDA’s Oncology Center of Excellence, discussed the FDA's pivotal role in fostering global collaboration, with over 500 applications and 400 approvals in the past five years. This approach has significantly accelerated patient access to new therapies worldwide. 2. ASCO’s Global Efforts - Julie Gralow, ASCO's Chief Medical Officer, highlighted efforts to break down silos and enhance communication among oncologists in low- and middle-income countries through regional councils. 3. NCI’s Collaborative Vision - Kimryn Rathmell, Director of the National Cancer Institute, spoke on the shift towards greater collaboration and innovation in clinical trials, aiming to make them faster and more accessible globally. Established in 2021 the coalition has been a major driving force in fostering international collaborations. By leveraging technology and bringing together multiple stakeholders from both the public and private sectors we focus on: 1. Improving access to diagnostics 2. Enhancing patient-centric cancer clinical trials through technologies like liquid biopsy and telemedicine 3. Promoting regulatory harmonization to lower barriers to patient-centric care globally This year, we welcome new members Tolulope Adewole of MedServe, Jennifer Dent of BVGH, Julie Gralow of ASCO, Tufia Haddad, M.D. of the Mayo Clinic Comprehensive Cancer Centre and Artur Katz of Hospital Sírio-Libanês, who are leaders in oncology and global health, further strengthening its commitment to global health equity. Read More: https://bloom.bg/4b0kZtW #InternationalCancerCoalition #ASCO2024

Join thoracic oncologist & early drug development specialist Dr. Bob Li today at 1:15pm (CT) as he discusses research on targeting KRAS in non-small cell lung cancer during a clinical science symposium at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Learn more: https://bit.ly/453CAA3 #ASCO24

Presentations by MSK researchers Drs. Bob Li, Helena Yu, and James Isbell at the American Society of Clinical Oncology (ASCO) Annual Meeting revealed encouraging clinical trial results and promise of a more sensitive “liquid biopsy,” all of which could improve lung cancer treatment. Learn more about their research: https://bit.ly/45cmKmB #ASCO24

Dr. Rick Pazdur, known as the “FDA Cancer Czar”, is widely feared by the pharmaceutical industry as each of his regulatory decisions may impact billions of dollars worldwide. However, all of us have a human story to tell in this growing international movement to accelerate the #Cure4Cancer. Watch our #Cure4Cancer interview with Dr. Pazdur to learn about his life journey, personal battles against cancer and his aspirations for advancing global clinical trials and health equity. Memorial Sloan Kettering Cancer Center Bloomberg New Economy Asia Society #cancer #oncology #clinicaltrials #international #collaboration #innovation #healthequity https://lnkd.in/e29zZQaz

Decentralized clinical trials represent a future, where patients and their experiences are at the center of oncology R&D. Instead of having patients jump through hoops to access clinical trials of novel treatments at a major academic cancer center, we bring the trial to the patient in their homes or local communities. In this first-of-its-kind study by Dr. Robert Daly at Memorial Sloan Kettering Cancer Center, Dr. Rick Pazdur at the FDA Oncology Center of Excellence and multi-stakeholder leaders at the Bloomberg New Economy International Cancer Coalition, we published pharma data on decentralized trials representing 33% of the global pharmaceutical industry by revenue. In the next 5 years, we will see a greater adoption of remote monitoring technologies and collaboration with local physician networks and imaging facilities to expand access to clinical trials globally. By leveraging technology and collaboration in patient-centric clinical trials, we may accelerate the #Cure4Cancer in this lifetime. Let's keep spreading the word, as we all have a role to play in this movement. #cancer #oncology #clinicaltrials #international #collaboration #technology https://lnkd.in/evW_b3qk